Invitek Diagnostics launches InviDx® System for rapid, decentralised molecular testing
New system launches with dedicated panels for pathogen and antimicrobial resistance gene detection, supporting molecular testing closer to where samples are collected.
9 September 2026 – Invitek Diagnostics has launched InviDx®, a new molecular testing platform developed to support rapid, decentralised detection of pathogens and antimicrobial resistance (AMR) genes.
The system combines three integrated components:
- The compact InviDx® instrument – designed for settings with limited laboratory infrastructure
- Dedicated molecular assays – application-specific panels for targeted detection
- The InviDx® Hub – a web-based application for automated result interpretation and reporting
Two dedicated assays at launch
InviScreen® UTI Pathogen Panel
Uses Loop-mediated Isothermal Amplification (LAMP) to simultaneously detect 10 microorganisms associated with urinary tract infections from urine samples. The complete workflow – sample preparation, amplification and automated result interpretation – provides results in under 60 minutes.
InviScreen® AMR Gene Panel
Extends the platform to antimicrobial resistance surveillance, enabling targeted screening of resistance genes using the same InviDx® system. Designed for research and One Health surveillance using purified DNA from human, animal, food and environmental sample sources.
Bringing molecular testing closer to the sample
InviDx® has been developed around the growing need for molecular testing outside centralised laboratory infrastructure.
This is particularly relevant for AMR surveillance. Resistance moves between human and animal populations, food systems and the environment, creating a need for surveillance approaches that can operate across the different sectors of One Health.
By combining a compact instrument with application-specific assays, InviDx® is designed to support molecular testing closer to where samples originate and broaden the settings in which targeted surveillance can take place.
“With InviDx®, we wanted to make molecular testing accessible in settings where conventional laboratory infrastructure can be a limiting factor. The launch is an important step for us, particularly in AMR, where faster and more distributed surveillance can help us understand how resistance is moving across human health, animals, food and the environment.”
Josué Carvalho, General Manager, Invitek Diagnostics
A platform built to grow
The launch of the first 2 panels establishes InviDx® as a platform rather than a single-purpose test.
Its assay-specific approach allows different molecular testing applications to run on the same instrument and software environment:
- The InviScreen® UTI Pathogen Panel detects 10 predefined pathogen targets in parallel from a single urine sample.
- The separately available AMR Gene Panel is dedicated to resistance gene detection across a variety of sample types, including clinical specimens, veterinary samples, microbial isolates from different sources, and wastewater.
InviDx® and its first panels are now available from Invitek Diagnostics.
Learn more about One Health and Antimicrobial Resistance →
About Invitek Diagnostics
Invitek Diagnostics develops and manufactures molecular biology products for sample preparation, nucleic acid extraction and molecular testing. Its technologies support applications across human health, veterinary research, food testing and environmental analysis, with a growing focus on One Health and antimicrobial resistance.